Semax in Mexico — guide and where to buy

Introduction

Semax is a synthetic heptapeptide studied as a nootropic and neuroprotective neuropeptide, with a preclinical literature concentrated in models of cerebral ischemia and of cognitive function, largely developed by research groups in Russia. In the Mexican research peptide market, its availability is more recent, which coexists with legitimate supply and resellers without analytical documentation.

This guide describes the structure of the compound, the nature of the available evidence, handling considerations for a receiving laboratory, and concrete steps to evaluate a vial on receipt. The focus is strictly technical and research-oriented.

What is Semax

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). It corresponds to the ACTH(4-7) fragment extended with a stabilizing Pro-Gly-Pro tail, a modification that prolongs its stability against enzymatic degradation. Unlike full ACTH, Semax lacks corticotropic activity. Its CAS number is 80714-61-0.

Among the reported preclinical mechanisms are modulation of the hippocampal BDNF/trkB system and effects on the expression of genes related to neurotransmitters and to inflammatory processes. Its molecular weight is approximately 813.93 Da, a value relevant for identity confirmation by mass spectrometry.

Preclinical evidence

Available evidence concentrates in animal models, primarily rodent, and in vitro systems. Among the most-cited studies is the protective effect described in a rat model of cerebral ischemia–reperfusion, published by Medvedeva and colleagues ^[1].

• Rat cerebral ischemia–reperfusion models: described neuroprotective effect ^[1].
• Modulation of the hippocampal BDNF/trkB system in preclinical models.
• Effects on the expression of genes related to neurotransmitters and inflammation.
• In vitro studies of neuronal survival and signaling.

The primary reference is Medvedeva EV, Dmitrieva VG, Limborska SA, et al. «Protective effect of the ACTH(4–7)PGP peptide (Semax) in a rat model of cerebral ischemia–reperfusion.» Int J Mol Sci. 2021;22(12) ^[1], available on PubMed (https://pubmed.ncbi.nlm.nih.gov/34201112/). Extrapolation of these findings to humans is not supported by an equivalent clinical body of work in high-impact journals, and Semax holds no FDA, EMA, or COFEPRIS approval for human use.

Research considerations

For a laboratory incorporating Semax into a protocol, operational considerations include presentation form, storage conditions, and study design. The standard presentation is sterile lyophilized in borosilicate vials. Reconstitution is performed with the diluent defined in the lab SOP, usually bacteriostatic water, depending on the experimental model.

• Store the lyophilized vial at −20 °C, protected from light and moisture.
• Reconstitute with sterile bacteriostatic water per the institutional SOP.
• Keep the compound in lyophilized form until the moment of use.
• Protect from light to limit peptide degradation.
• Aliquot the reconstituted solution to avoid repeated thermal cycles.

Study design must comply with applicable animal ethics protocols (NOM-062-ZOO-1999 in Mexico) and be authorized by the institutional committee. Use outside an authorized protocol does not fall within the scientific research framework.

How to evaluate a vial

Evaluating a Semax vial on receipt follows the same criteria as any research peptide, with emphasis on analytical traceability. HPLC purity stated in the COA must be ≥99%, with the chromatogram of the specific lot. Identity by mass spectrometry must show an observed mass consistent with the theoretical molecular weight of the heptapeptide (approximately 813.93 Da).

1. Verify the COA corresponds to the physical lot of the vial received.
2. Confirm HPLC purity ≥99% with attached chromatogram.
3. Confirm identity by MS: observed mass vs. theoretical mass.
4. Review batch traceability from synthesis to the final vial.
5. Inspect the lyophilizate: uniform solid, no particles or moisture.

MX-1 Labs distributes Semax as a research compound from CDMX, with per-batch COA and MS-confirmed identity; the per-batch retention sample is held by the synthesizing lab. For a Mexican laboratory, this combination of analytical documentation and domestic origin simplifies audits and reduces transit times.

Conclusion

Semax is a neuropeptide with preclinical literature oriented toward neuroprotective mechanisms and modulation of the BDNF/trkB system, but without formal clinical validation in high-impact journals. Its incorporation into a research protocol requires robust analytical documentation from the supplier, handling conditions defined in the SOP, and an experimental design authorized by the institutional committee. Supplier choice must rest on verifiable criteria, not commercial messaging.

This article is educational only. Semax is not a medication or a product for human consumption and is distributed solely as a material for research use only in the laboratory.